U.S. product mix sustainability
Q2 gross margin benefited from favorable U.S. product mix, which may not persist in coming quarters, potentially pressuring margins.
medium · management_commentaryAlkem Laboratories Limited — Q2 FY24
Alkem delivered a strong Q2 with 12% YoY revenue growth and EBITDA margin of 21.7%, well above the full-year guidance of ~16.5%.
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Dabigatran supply chain challenges
Despite being one of two approved generics, supply chain issues persist due to FDA-dependent secondary API source; no near-term resolution.
medium · analyst_questionPen G price uncertainty
Pen G prices remain elevated at $28-30 vs pre-COVID $8-10; any further increase or delayed normalization could hurt gross margins.
medium · analyst_questionSluggish domestic acute business
India acute business underperformed due to delayed monsoons; recovery depends on seasonality and may not sustain.
low · management_commentary